Cargando…

How do we define high and low dose intensity of heart failure medications: a scoping review

BACKGROUND: Older adults with heart failure often experience adverse drug events with high doses of heart failure medications. Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Min Ji, Wang, Qian, Onyebeke, Chukwuma, Holder, Travis, Goyal, Parag, Aparasu, Rajender, Dhoble, Abhjeet, Holmes, Holly M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523693/
https://www.ncbi.nlm.nih.gov/pubmed/37759279
http://dx.doi.org/10.1186/s12872-023-03514-2
_version_ 1785110614300950528
author Kwak, Min Ji
Wang, Qian
Onyebeke, Chukwuma
Holder, Travis
Goyal, Parag
Aparasu, Rajender
Dhoble, Abhjeet
Holmes, Holly M.
author_facet Kwak, Min Ji
Wang, Qian
Onyebeke, Chukwuma
Holder, Travis
Goyal, Parag
Aparasu, Rajender
Dhoble, Abhjeet
Holmes, Holly M.
author_sort Kwak, Min Ji
collection PubMed
description BACKGROUND: Older adults with heart failure often experience adverse drug events with high doses of heart failure medications. Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician on which symptoms to look for, whether from overdosing or underdosing. However, the current guideline does not provide sufficient information about the dose intensity below the target dose. Furthermore, the definition of high or low-intensity heart failure medication is unclear, and there is no consensus. METHODS: To close the knowledge gap, we conducted a scoping review of the current literature to identify the most frequently used definition of high versus low doses of heart failure medications. We searched Pubmed, Embase, CINAHL, and Cochrane Library using comprehensive search terms that can capture the intensity of heart failure medications. RESULTS: We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI). For hydralazine with isosorbide dinitrate or ivabradine, we could not identify any eligible articles. We identified 40 medications with most frequently used definitions of dose intensity. Four medications (nadolol, pindolol, cilazapril, and torsemide) did not reach consensus in definitions. Most of the BBs, ACEis, or ARBs used the definition of low being < 50% of the target dose and high being ≥ 50% of the target dose from the guideline. However, for lisinopril and losartan, the most commonly used definitions of high or low were from pivotal clinical trials with a pre-defined definition of high or low. CONCLUSION: Our comprehensive scoping review studies identified the most frequently used definition of dose intensity for 40 medications but could not identify the definitions for 4 medications. The results of the current scoping review will be helpful for clinicians to have awareness whether the currently prescribed dose is considered high - requiring close monitoring of side effects, or low - requiring more aggressive up-titration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03514-2.
format Online
Article
Text
id pubmed-10523693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105236932023-09-28 How do we define high and low dose intensity of heart failure medications: a scoping review Kwak, Min Ji Wang, Qian Onyebeke, Chukwuma Holder, Travis Goyal, Parag Aparasu, Rajender Dhoble, Abhjeet Holmes, Holly M. BMC Cardiovasc Disord Research BACKGROUND: Older adults with heart failure often experience adverse drug events with high doses of heart failure medications. Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician on which symptoms to look for, whether from overdosing or underdosing. However, the current guideline does not provide sufficient information about the dose intensity below the target dose. Furthermore, the definition of high or low-intensity heart failure medication is unclear, and there is no consensus. METHODS: To close the knowledge gap, we conducted a scoping review of the current literature to identify the most frequently used definition of high versus low doses of heart failure medications. We searched Pubmed, Embase, CINAHL, and Cochrane Library using comprehensive search terms that can capture the intensity of heart failure medications. RESULTS: We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI). For hydralazine with isosorbide dinitrate or ivabradine, we could not identify any eligible articles. We identified 40 medications with most frequently used definitions of dose intensity. Four medications (nadolol, pindolol, cilazapril, and torsemide) did not reach consensus in definitions. Most of the BBs, ACEis, or ARBs used the definition of low being < 50% of the target dose and high being ≥ 50% of the target dose from the guideline. However, for lisinopril and losartan, the most commonly used definitions of high or low were from pivotal clinical trials with a pre-defined definition of high or low. CONCLUSION: Our comprehensive scoping review studies identified the most frequently used definition of dose intensity for 40 medications but could not identify the definitions for 4 medications. The results of the current scoping review will be helpful for clinicians to have awareness whether the currently prescribed dose is considered high - requiring close monitoring of side effects, or low - requiring more aggressive up-titration. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03514-2. BioMed Central 2023-09-27 /pmc/articles/PMC10523693/ /pubmed/37759279 http://dx.doi.org/10.1186/s12872-023-03514-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kwak, Min Ji
Wang, Qian
Onyebeke, Chukwuma
Holder, Travis
Goyal, Parag
Aparasu, Rajender
Dhoble, Abhjeet
Holmes, Holly M.
How do we define high and low dose intensity of heart failure medications: a scoping review
title How do we define high and low dose intensity of heart failure medications: a scoping review
title_full How do we define high and low dose intensity of heart failure medications: a scoping review
title_fullStr How do we define high and low dose intensity of heart failure medications: a scoping review
title_full_unstemmed How do we define high and low dose intensity of heart failure medications: a scoping review
title_short How do we define high and low dose intensity of heart failure medications: a scoping review
title_sort how do we define high and low dose intensity of heart failure medications: a scoping review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523693/
https://www.ncbi.nlm.nih.gov/pubmed/37759279
http://dx.doi.org/10.1186/s12872-023-03514-2
work_keys_str_mv AT kwakminji howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT wangqian howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT onyebekechukwuma howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT holdertravis howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT goyalparag howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT aparasurajender howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT dhobleabhjeet howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview
AT holmeshollym howdowedefinehighandlowdoseintensityofheartfailuremedicationsascopingreview